SVRA - NASDAQ

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%

HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.08B

EPS-0.5300

P/E Ratio-9.91

Earnings Date08/06/2026

svra

Total Debt

Last Annual Value

29.91M

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Savara Inc. Competitors Analysis of Total Debt

SVRA · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Savara Inc. NASDAQ:SVRA	29.91M	4.1%	3.0%	20.9%
Kura Oncology, Inc. NASDAQ:KURA	20.46M	6.0%	24.4%	10.8%
Geron Corporation NASDAQ:GERN	251.57M	43.1%	35.5%	N/A
Rezolute, Inc. NASDAQ:RZLT	1.61M	-13.3%	-35.5%	34.5%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	1.71M	37.6%	N/A	N/A
Tango Therapeutics, Inc. NASDAQ:TNGX	33.57M	-4.8%	86.1%	N/A
Tyra Biosciences, Inc. NASDAQ:TYRA	5.81M	-3.7%	37.5%	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	20.77M	61.8%	-11.9%	N/A
ProKidney Corp. NASDAQ:PROK	2.96M	-12.4%	17.3%	N/A

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

HIDDEN

Intrinsic Value

Current Price: $5.25

Related Guides

Blog Categories

Continue your SVRA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.